The raise will go toward trialing the company’s lead drug for phosphomannomutase-2 congenital disorder of glycosylation, a ...

The biotech is developing an experimental drug for the most common of a family of disorders all caused by errors in ...

Learn more about whether Amicus Therapeutics, Inc. or Moderna, Inc. is a better investment based on AAII's A+ Investor grades ...

RFK Jr.'s Health Department shut down an advisory group that recommends how to test newborns for genetic disorders ...

Sanofi has added another string to its Pompe disease therapy bow, after getting FDA approval for Nexviazyme, its latest therapy for the rare, inherited disorder. The US regulator has approved ...

Dyne Therapeutics, Inc.’s DYN share price has surged by 6.89%, which has investors questioning if this is right time to sell.

Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases, today announced ...

Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases, today announced ...

Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on advancing life-transforming therapeutics for people living with genetically ...

AB-1002 is one of several clinical-stage gene therapy programmes being run by AskBio, along with candidates for Pompe disease, Parkinson’s disease, Huntington’s disease, multiple system ...

Meeting is the largest gathering of competition, consumer protection, and data privacy profes­sionals globally, with lawyers, ...

June 10, 2024 — Scientists have grown 'mini-guts' in the lab to help understand Crohn's disease, showing that 'switches' that modify DNA in gut cells play an important role in the disease ...